These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 2688995

  • 1. Nasal calcitonin for treatment of established osteoporosis.
    Overgaard K, Riis BJ, Christiansen C, Pødenphant J, Johansen JS.
    Clin Endocrinol (Oxf); 1989 Apr; 30(4):435-42. PubMed ID: 2688995
    [Abstract] [Full Text] [Related]

  • 2. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
    Kaskani E, Lyritis GP, Kosmidis C, Galanos A, Andypas G, Chorianopoulos K, Giagiosis A, Iliadou K, Karagianis A, Katsimichas K, Koskinas A, Matsouka K.
    Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
    [Abstract] [Full Text] [Related]

  • 3. Discontinuous calcitonin treatment of established osteoporosis--effects of withdrawal of treatment.
    Overgaard K, Hansen MA, Nielsen VA, Riis BJ, Christiansen C.
    Am J Med; 1990 Jul; 89(1):1-6. PubMed ID: 2152594
    [Abstract] [Full Text] [Related]

  • 4. Effect of nasal salmon calcitonin on bone remodeling and bone mass in postmenopausal osteoporosis.
    Thamsborg G, Jensen JE, Kollerup G, Hauge EM, Melsen F, Sorensen OH.
    Bone; 1996 Feb; 18(2):207-12. PubMed ID: 8833216
    [Abstract] [Full Text] [Related]

  • 5. Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis.
    Adami S, Passeri M, Ortolani S, Broggini M, Carratelli L, Caruso I, Gandolini G, Gnessi L, Laurenzi M, Lombardi A.
    Bone; 1995 Oct; 17(4):383-90. PubMed ID: 8573412
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Early effect of nasal salmon calcitonin on the bone marker Crosslaps.
    Ofluoglu D, Karadag-Saygi E, Canbulat C, Gunduz OH, Kul-Panza E, Akyuz G.
    Rheumatol Int; 2006 Feb; 26(4):288-91. PubMed ID: 15875189
    [Abstract] [Full Text] [Related]

  • 8. The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin.
    Tascioglu F, Colak O, Armagan O, Alatas O, Oner C.
    Rheumatol Int; 2005 Nov; 26(1):21-9. PubMed ID: 15688191
    [Abstract] [Full Text] [Related]

  • 9. A double blind study of intranasal calcitonin for established postmenopausal osteoporosis.
    Kapetanos G, Symeonides PP, Dimitriou C, Karakatsanis K, Potoupnis M.
    Acta Orthop Scand Suppl; 1997 Oct; 275():108-11. PubMed ID: 9385282
    [Abstract] [Full Text] [Related]

  • 10. [Clinical efficacy of treatment with salmon calcitonin, administered intranasally for 1 year, in stabilized postmenopausal osteoporosis].
    Agnusdei D, Gonnelli S, Camporeale A, Batignani T, Nardi P, Ianes A, Gennari C.
    Minerva Endocrinol; 1989 Oct; 14(3):169-76. PubMed ID: 2695815
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Estimation of the effect of salmon calcitonin in established osteoporosis by biochemical bone markers.
    Nielsen NM, von der Recke P, Hansen MA, Overgaard K, Christiansen C.
    Calcif Tissue Int; 1994 Jul; 55(1):8-11. PubMed ID: 7922794
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Nasal salmon calcitonin blunts bone microstructure alterations in healthy postmenopausal women.
    Rizzoli R, Sigaud A, Azria M, Herrmann FR.
    Osteoporos Int; 2015 Jan; 26(1):383-93. PubMed ID: 25566730
    [Abstract] [Full Text] [Related]

  • 15. Nandrolone decanoate and intranasal calcitonin as therapy in established osteoporosis.
    Flicker L, Hopper JL, Larkins RG, Lichtenstein M, Buirski G, Wark JD.
    Osteoporos Int; 1997 Jan; 7(1):29-35. PubMed ID: 9102059
    [Abstract] [Full Text] [Related]

  • 16. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial.
    Binkley N, Bolognese M, Sidorowicz-Bialynicka A, Vally T, Trout R, Miller C, Buben CE, Gilligan JP, Krause DS, Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) Investigators.
    J Bone Miner Res; 2012 Aug; 27(8):1821-9. PubMed ID: 22437792
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Treatment of postmenopausal osteoporosis with salmon calcitonin nasal spray: evaluation by bone mineral content and biochemical patterns.
    Tolino A, Romano L, Ronsini S, Riccio S, Montemagno U.
    Int J Clin Pharmacol Ther Toxicol; 1993 Jul; 31(7):358-60. PubMed ID: 8370634
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effects of salmon calcitonin suppositories on bone mass and turnover in established osteoporosis.
    Kollerup G, Hermann AP, Brixen K, Lindblad BE, Mosekilde L, Sørensen OH.
    Calcif Tissue Int; 1994 Jan; 54(1):12-5. PubMed ID: 8118746
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.